OncoPharm

ADAM VTE (apixaban for cancer-associated VTE) results have been published - let's talk about it. Also, what are the implications of long term ibrutinib on CV health? A new Blood paper offers some possible answers.

Dive into the complex world of immunotherapy rechallenge, where experts weigh the risks and benefits for patients with prior immune-related adverse events. Discover case studies that illuminate the importance of shared decision-making and careful patient monitoring. Explore strategies for managing lower-grade toxicity and the challenges faced during cancer treatment. With valuable insights into timing and management protocols, this discussion is vital for anyone interested in cutting-edge cancer care.

Reviewing the recent Lancet publication of CASPIAN (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)32222-6/fulltext) --> durvalumab + chemo in extensive stage small cell lung cancer.

Recapping updates from ESMO 2019. Topics include FLAURA (osimertinib), 5-year OS analyses of immunotherapy in metastatic NSCLC & melanoma, EGFR/BRAF/MEK inhibition in BRAF-V600E colorectal cancer, PARP inhibitors in ovarian cancer, and a possible cabazitaxel comeback.

The Landmarks in #Oncopharm series returns on the 10-year anniversary of this landmark paper (https://www.nejm.org/doi/10.1056/NEJMoa0904544) comparing daunorubicin 90 mg/m2 vs. 45 mg/m2 for AML induction.

Discussion of FDA's approval of lenvatinib & pembrolizumab for endometrial cancer followed by a comparison of TITAN v. ENZAMET prompted by apalutamide's latest approval.

Recapping the NY Times (https://www.nytimes.com/interactive/2018/10/26/magazine/netflix-diagnosis-series-joe.html) & Netflix collaboration "Diagnosis" about a possible Ibrutinib ADR. We also the discuss the value of case reports for the #OncoPharm community.

The 2nd installment of the OncoPharm Morbidity & Mortality series discussed a published case report (https://www.ncbi.nlm.nih.gov/pubmed/28782406). We discuss the approach to take when a patient experiences unexpectedly extreme toxicity and the role pharmacogenetics may play. Suggested resource: https://cpicpgx.org

Dive into the fascinating world of irinotecan, a chemotherapy drug rooted in the ancient use of camptothecin. Explore how genetic differences impact treatment outcomes and side effects. Learn about the drug's complex dosing considerations and the notorious issue of diarrhea. Discover recent innovations, like the FDA-approved liposomal formulation, and how pharmacogenetic insights are reshaping personalized cancer care.

Running through the drug information highlights of the latest approved #oncopharm agents: entrectinib and fedratinib.